Assessing Candidate IGF-1 Receptor Inhibitors for the Ability to Modestly Slow Aging in Mice

Key Takeaways

• IGF‑1R inhibitors improved memory, blood pressure, and grip strength
• NVP‑ADW742 added ~93 days of healthspan in mice
• PPP caused gastrointestinal bleeding; NVP‑ADW742 showed cardiotoxic signals
• No significant lifespan increase detected in treated groups
• Findings support IGF‑1 pathway as anti‑aging target, pending safety fixes

Pulse Analysis

The insulin‑IGF‑1‑growth hormone axis has long been recognized as a master regulator of the trade‑off between growth and maintenance. In rodents, genetic ablation of growth‑hormone or IGF‑1 receptors produces dwarf phenotypes that live up to 70 % longer than normal littermates, a striking proof that dampening this pathway can extend lifespan. Human parallels, such as Laron syndrome, reveal modest disease resistance but no dramatic longevity gains, underscoring species‑specific constraints. Consequently, pharmaceutical strategies aim to mimic the beneficial aspects of calorie restriction by selectively blocking IGF‑1 signaling without the need for lifelong genetic alteration.

The open‑access study evaluated two orally bioavailable small‑molecule IGF‑1R antagonists—picropodophyllin (PPP) and NVP‑ADW742—in 13‑month‑old C57BL/6 mice, with equal numbers of males and females. Both compounds preserved short‑term memory, lowered systolic pressure in males, reduced pulse rate across sexes, and improved glucose tolerance in males. Female mice showed reduced frailty, maintained grip strength, and avoided grey‑hair onset. Notably, NVP‑ADW742 produced a “squarer” survival curve, translating to roughly 93 extra days of healthspan, although overall lifespan curves did not diverge significantly. Toxicity emerged as a critical issue: PPP induced gastrointestinal bleeding, while NVP‑ADW742 flagged potential cardiotoxicity and brain bioaccumulation.

These results reinforce the IGF‑1 receptor as a viable anti‑aging target, yet they also illustrate the narrow therapeutic window that any drug must navigate. Compared with calorie‑restriction mimetics such as metformin or rapamycin, IGF‑1R inhibitors may deliver more direct modulation of growth pathways, potentially yielding sharper healthspan benefits. However, safety concerns will dominate regulatory scrutiny and investor confidence. Future work will need to refine molecular selectivity, improve pharmacokinetics, and perhaps combine low‑dose IGF‑1R blockade with other geroprotectors to offset adverse effects. If these hurdles are cleared, the market for longevity therapeutics—projected to reach tens of billions of dollars—could expand dramatically.